Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Neuropace Inc before investing.

In this article, we go over a few key elements for understanding Neuropace Inc’s stock price such as:

• Neuropace Inc’s current stock price and volume
• Why Neuropace Inc’s stock price changed recently
• Upgrades and downgrades for NPCE from analysts
• NPCE’s stock price momentum as measured by its relative strength

About Neuropace Inc (NPCE)

Before we jump into Neuropace Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company?s differentiated RNS System is a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company is developing its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. RNS System is a device that records brain activity data and allows clinicians to monitor patients. RNS System monitors the brain?s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company?s RNS System is engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Want to learn more about Neuropace Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Neuropace Inc.

Neuropace Inc’s Stock Price as of Market Close

As of March 19, 2024, 4:00 PM, CST, Neuropace Inc’s stock price was $13.45.

Neuropace Inc is up 4.75% from its previous closing price of $12.84.

During the last market session, Neuropace Inc’s stock traded between $12.84 and $13.35. Currently, there are 26.81 million shares of Neuropace Inc stock available for purchase.

Unfortunately, Neuropace Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Neuropace Inc Stock Price History

Neuropace Inc’s (NPCE) price is currently down 16.82% so far this month.

During the month of March, Neuropace Inc’s stock price has reached a high of $16.88 and a low of $12.63.

Over the last year, Neuropace Inc has hit prices as high as $18.15 and as low as $3.42. Year to date, Neuropace Inc’s stock is up 802.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Neuropace Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 18, 2024, there were 0 analysts who downgraded Neuropace Inc’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Neuropace Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Neuropace Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Neuropace Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Neuropace Inc (NPCE) by visiting AAII Stock Evaluator.

Relative Price Strength of Neuropace Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 18, 2024, Neuropace Inc has a weighted four-quarter relative price strength of 31.31%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Neuropace Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Neuropace Inc Stock Price: Bottom Line

As of March 19, 2024, Neuropace Inc’s stock price is $13.45, which is up 4.75% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Neuropace Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.